A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Description

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

Conditions

Geographic Atrophy, Macular Degeneration

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Condition
Geographic Atrophy
Intervention / Treatment

-

Contacts and Locations

Tucson

Retina Associates Southwest PC, Tucson, Arizona, United States, 85704

Fullerton

Retina Consultants of Orange County, Fullerton, California, United States, 92835

Walnut Creek

Bay Area Retina Associates, Walnut Creek, California, United States, 94598

Gainesville

VitreoRetinal Associates, PA, Gainesville, Florida, United States, 32607

Pensacola

Retina Specialty Institute, Pensacola, Florida, United States, 32503

Marietta

Marietta Eye Clinic, Marietta, Georgia, United States, 30060

Portland

Maine Eye Center, Portland, Maine, United States, 04101

Hagerstown

Cumberland Valley Retina Consultants, Hagerstown, Maryland, United States, 21740

Grand Rapids

Foundation for Vision Research, Grand Rapids, Michigan, United States, 49546

Saint Louis

The Retina Institute, Saint Louis, Missouri, United States, 63144

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)
  • * Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study
  • * Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations
  • * There are no exclusion criteria for this LTE study

Ages Eligible for Study

60 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Janssen Research & Development, LLC,

Janssen Research & Development, LLC Clinical Trial, STUDY_DIRECTOR, Janssen Research & Development, LLC

Study Record Dates

2029-12-03